Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Uniqure Ord Shs (NQ: QURE )

6.675 -0.115 (-1.69%)
Streaming Delayed Price Updated: 12:43 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Uniqure Ord Shs

< Previous 1 2 3 4 5 Next >
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring 
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst
uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare  
Via Benzinga
6 Analysts Have This to Say About uniQure
Via Benzinga
Analyst Ratings for uniQure
Via Benzinga
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
From uniQure Inc.
Via GlobeNewswire
Recap: uniQure Q1 Earnings
uniQure (NASDAQ:QURE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:05 AM. Here's what investors need to know about the announcement. Earnings uniQure missed estimated earnings by... 
Via Benzinga
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
uniQure to Participate in Multiple Upcoming Industry Conferences in March
From uniQure Inc.
Via GlobeNewswire
uniQure Stock Trying To Close In On Key Technical Measure
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
From uniQure Inc.
Via GlobeNewswire
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
From uniQure Inc.
Via GlobeNewswire
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). 
Via Benzinga
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
From uniQure Inc.
Via GlobeNewswire
3 Growth Stocks That Could Rocket Higher in 2023
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
Newly Approved Drugs In US Command Over $200,000 On An Average
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B 
From uniQure Inc.
Via GlobeNewswire
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
From uniQure Inc.
Via GlobeNewswire
Why Shares of uniQure Rose 14.61% on Wednesday
A big approval for a gene therapy sent the biotech's stock higher. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
And shares of its developer are on a warpath this week. 
Via Investor's Business Daily
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.